Castle biosciences announces publication of clinical utility, long-term outcomes data and meta-analysis for decisiondx-um for patients with uveal melanoma

Castle biosciences, inc. (nasdaq: cstl), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment deci

CSTL Ratings Summary

CSTL Quant Ranking